Overview

Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation

Status:
Active, not recruiting

Trial end date:
2021-06-11

Target enrollment:

Participant gender:

Summary

Sacubitril-valsartan, an Angiotensin Receptor Blocker-Neprilysin Inhibitor (ARNI), currently marketed for the management of heart failure, has been shown to reduce cardiovascular morbidity and mortality in stage C heart failure with reduced ejection fraction. In stage C HFpEF, sacubitril-valsartan has also been shown to reduce left atrial volume index measured using echocardiography over a 9 month timeframe. The PARABLE study investigates the hypothesis that sacubitril-valsartan can provide benefits in terms of left atrial structure and function as well as left ventricular structure and function in asymptomatic (stage A/B HFpEF) patients. This is a prospective, randomised, double-blind, double-dummy, phase II study design. The patient population will have hypertension and/or diabetes together with preserved ejection fraction, elevated natriuretic peptide (NP) and abnormal left atrial volume index (LAVI, > 28 mL/m2).

Phase:

Phase 2

Details

Lead Sponsor:

Mark Ledwidge

Collaborator:

The Heartbeat Trust

Treatments:

LCZ 696
Sacubitril and valsartan sodium hydrate drug combination
Valsartan